We are live on ! Find out more
HVC

Healthcare Value Capital Portfolio holdings

AUM $50.7M
1-Year Est. Return 24.72%
This Fund
S&P 500
This Quarter Est. Return
+3.1%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$26M
AUM Growth
+$228K
Cap. Flow
-$400K
Cap. Flow %
-1.54%
Top 10 Hldgs %
100%
Holding
13
New
3
Increased
2
Reduced
–
Closed
3

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$3.32M
2
AGN
Allergan plc
AGN
+$1.45M
3
VKTX icon
Viking Therapeutics
VKTX
+$1.26M
4
ADMS
Adamas Pharmaceuticals
ADMS
+$899K

Top Sells

Rank Stock Value
1
LAB icon
Standard BioTools
LAB
+$3.88M
2
BIS icon
ProShares UltraShort NASDAQ Biotechnology
BIS
+$3.45M

Sector Composition

Rank Sector Weight
1 Healthcare 84.06%
2 Miscellaneous 15.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGN
1
DELISTED
Allergan plc
AGN
$4.39M 16.92%
30,000
+10,000
+50% +$1.45M
GSK icon
2
GSK
GSK
$101B
$4.18M 16.1%
80,000
– –
TYME
3
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
$3.83M 14.75%
2,175,000
– –
GILD icon
4
Gilead Sciences
GILD
$184B
$3.25M 12.53%
+50,000
New +$3.32M
LGND icon
5
PUT
Ligand Pharmaceuticals
LGND
$5.67B
$3.14M 12.11%
+40,075
New +$3.04M
VKTX icon
6
Viking Therapeutics
VKTX
$3.95B
$2.48M 9.57%
250,000
+150,000
+150% +$1.26M
NVLN
7
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$2.21M 8.53%
1,800,000
– –
VKTX icon
8
CALL
Viking Therapeutics
VKTX
$3.95B
$994K 3.83%
100,000
– –
ATRS
9
DELISTED
Antares Pharma, Inc.
ATRS
$758K 2.92%
250,000
– –
ADMS
10
DELISTED
Adamas Pharmaceuticals
ADMS
$711K 2.74%
+100,000
New +$899K
BIS icon
11
ProShares UltraShort NASDAQ Biotechnology
BIS
$1.77M
– –
-18,750
Closed -$3.45M
LAB icon
12
Standard BioTools
LAB
$252M
– –
-450,000
Closed -$3.88M
LCI
13
CALL
DELISTED
Lannett Company, Inc.
LCI
– –
-6,250
Closed -$124K

Similar funds

C
Castlelake Minneapolis, Minnesota $48.5M AUM 87.77% 1-Year Est. Return
CC
Cedar Capital Barrington, Illinois $54.9M AUM 33.3% 1-Year Est. Return
FCOI
FirstMark Capital OF II New York $44.1M AUM 18.15% 1-Year Est. Return
FCOI
FirstMark Capital OF I New York $43.1M AUM 6.31% 1-Year Est. Return
BI
BCBSM Inc Eagan, Minnesota $42.4M AUM 0.4% 1-Year Est. Return
KC
Kelso & Company New York $42.3M AUM
SCIM
Spring Creek Investment Management Philadelphia, Pennsylvania $42.3M AUM 31.86% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Healthcare Value Capital's Q1 2019 Portfolio in Review

As of Q1 2019, Healthcare Value Capital held 13 positions worth $26M, up 0.89% from $25.7M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Healthcare Value Capital's Q1 2019 filing shows 3 new, 2 increased and 3 closed positions. Its largest new stake was Gilead Sciences: 50,000 shares worth $3.25M. The largest sale was Standard BioTools, an estimated $3.88M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 83% a quarter earlier, followed by Miscellaneous.

  • Healthcare Value Capital's largest Q1 2019 buy was Gilead Sciences: 50,000 shares worth $3.25M.
  • Healthcare Value Capital added most to Allergan plc in Q1 2019, an estimated $1.45M increase.
  • Healthcare Value Capital fully exited Standard BioTools in Q1 2019, selling an estimated $3.88M.
  • Healthcare Value Capital's ten largest holdings make up 100% of its $26M portfolio in Q1 2019.
  • Healthcare Value Capital opened 3 new positions and closed 3 in Q1 2019.
  • Healthcare Value Capital's portfolio value rose 0.89% quarter-over-quarter to $26M.

Based on Healthcare Value Capital's 13F filing for Q1 2019, filed 14 May 2019.